Loading stock data…
SLGL
$76.22-3.78 (-4.72%)
Market ClosedLast close Jun 9
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sol-Gel Technologies Ltd. in the Healthcare sector is trading at $76.22. Wall Street consensus targets $147.00 (2 analysts), implying a +92.9% move over the next 12 months. The stock is currently 22% below its 52-week high of $97.97, remaining 37.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +92.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$76.22
Potential Downside
0%
Whystock Fair Value$76.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$147.00+92.9%
Range$110.00 – $184.00
Fundamentals
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The compan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.03%
Volume
Today's trading volume
41,498
Recent News
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
SolGel Technologies (SLGL) delivered earnings and revenue surprises of +28.80% and -88.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
US Equity Indexes Fall Amid Uncertainty Over US-Iran Truce Talks
US equity indexes fell on Tuesday as oil prices continued to rise amid uncertainty surrounding truce
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
SolGel Technologies (SLGL) delivered earnings and revenue surprises of -374.36% and -89.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last year
Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit...
We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, Sol-Gel...